Trevena Inc represents core values such as innovation, scientific excellence, and commitment to improving patient outcomes. With a strong corporate philosophy, the company aims to transform patient care by developing and delivering innovative therapies. Trevena Inc focuses on creating value for patients, healthcare providers, and shareholders by developing cutting-edge medicines that address unmet medical needs. By harnessing their expertise in G protein-coupled receptor (GPCR) biology, the company strives to develop differentiated drugs that provide superior therapeutic benefits. Trevena Inc's dedication to research and development, coupled with their patient-centric approach, positions them as a leader in the pharmaceutical industry.

Trevena Inc is primarily present in the United States.

Trevena Inc has achieved several significant milestones in its history. The company successfully received U.S. FDA approval for OLINVYK™ (oliceridine) injection, its first commercial product, in August 2020. This milestone marked a major accomplishment for Trevena Inc in providing a new treatment option for moderate to severe acute pain. Additionally, Trevena Inc has successfully advanced its pipeline of novel therapies, including TRV250 for acute migraine and TRV734 for neurogenic itch. These achievements highlight the company's commitment to developing innovative solutions and enhancing patient care in various therapeutic areas.

Trevena Inc is a pharmaceutical company with a rich history and background. Founded in 2007, the company is headquartered in Pennsylvania, USA. Trevena Inc focuses on developing innovative therapies for patients suffering from central nervous system disorders. The company has made significant advancements in the field of biotechnology, particularly in their development of G protein-coupled receptor (GPCR) targeted medicines. Trevena Inc has received numerous accolades and recognition for its commitment to scientific research and dedication to improving patient outcomes. With a strong team of experts and a robust portfolio of drug candidates, Trevena Inc continues to strive towards providing breakthrough treatments for patients worldwide.

The main competitors of Trevena Inc in the market include pharmaceutical companies such as Pfizer, Novartis, and Johnson & Johnson.

Trevena Inc is primarily active in the pharmaceutical industry.

The business model of Trevena Inc revolves around developing and commercializing innovative therapies for patients suffering from central nervous system (CNS) disorders. The company focuses on identifying and targeting G protein-coupled receptors (GPCRs) to develop new drugs. Trevena Inc utilizes its proprietary drug discovery platform to design and develop differentiated candidates that have the potential to address significant unmet medical needs. Through strategic collaborations and licensing agreements, Trevena Inc aims to maximize the reach and impact of its novel therapies, ultimately improving patient outcomes and creating value for its shareholders.

P/E odnos Trevena iznosi -0,11.

KUV kompanije Trevena iznosi 302,64.

AlleAktien kvalitativni skor za Trevena je 5/10.

očekivana Trevena promet je 10.200,00 USD.

Dobit očekivana Trevena je -27,42 mil. USD.

Trevena Inc is an innovative biotechnology company that aims to revolutionize the treatment of severe diseases. The company's business model is based on the research, development, and marketing of drugs that target a new class of G protein-coupled receptors to optimize the effects of medications. Trevena focuses on developing new and innovative therapeutics to combat severe diseases such as pain, respiratory, and cardiovascular diseases. The company develops drugs that can alleviate the symptoms of these diseases and significantly improve patients' quality of life. One product currently in the final phase of clinical trials is Oliceridine injection (marketed as "Olinvo"), a treatment for acute pain that can occur in patients during and after surgery. Trevena's added value lies in discovering and selecting novel G protein-coupled receptors that have proven to be uniquely effective. The company has the ability to identify innovative drug candidates with high potency and improved safety and tolerability profiles. Through their proprietary platform and expertise in preclinical and clinical research, Trevena can efficiently and rapidly develop innovative drugs. The company operates on a three-stage business model. The first phase involves the discovery and selection of drug candidates, which are then tested for efficacy and tolerability in preclinical studies. In the second phase, the company conducts clinical trials, testing the drugs on healthy subjects and later on patients with specific diseases. The final phase is the approval and commercialization of drugs that successfully pass the clinical trials and receive approval from regulatory authorities. Trevena has an extensive pipeline of drug candidates at various stages of development. In addition to Oliceridine injection, the company is developing TRV250 (marketed as "Pullevin"), a drug for the treatment of migraine attacks and dizziness caused by overactivation of specific G protein-coupled receptors. Also in Trevena's pipeline is TRV734, a pain medication that targets the effects of opioid medications, which have a high potential for dependence. Overall, Trevena has a solid business model with the potential to bring innovative and much-needed medications to the market. With its proprietary platform and expertise in preclinical and clinical research, the company aims to elevate the treatment of severe diseases to a new level.

Trevena isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Trevena trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Trevena je US89532E1091.

WKN od Trevena je A1XDSL.

Oznaka za praćenje akcija kompanije Trevena je TRVN.

U poslednjih 12 meseci, Trevena je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Trevena će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Trevena trenutno iznosi .

Trevena isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Trevena je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Trevena se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Trevena od 18. 7. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 18. 7. 2024..

Isplata poslednje dividende izvršena je 18. 7. 2024..

U godini 2023 kompanija Trevena je isplatila 0 USD kao dividende.

Dividende od Trevena se isplaćuju u USD.